European Society for Medical Oncology (ESMO) Congress 2025

Berlin, Germany

The abstract, a Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours by Perez et al, will be presented as a poster (# 967P) on Sunday, October 19 from 12:00-12:45 CEST.